John B. Amos Cancer Center - Columbus Regional Health

The John B. Amos Cancer Center is a multi-disciplinary cancer center accredited by the Commission on Cancer of the American College of Surgeons as a Community Hospital Comprehensive Cancer Program – the only treatment center to be so named in the 14-county service area of Columbus, Georgia. The center is also accredited by the American College of Radiology (ACR). The John B. Amos Cancer Center is a recipient of the Georgia Cancer Coalition Distinguished Cancer Scholars Award, which supports leaders who are engaged in the most promising areas of cancer research. John B. Amos is a member of the Atlanta Regional Community Clinical Oncology Program (ARCCOP), a program initiated by the National Cancer Institute (NCI) to provide community hospitals access to a wide range of clinical research studies. The center is also a member of the Georgia CORE Research Network, a statewide network of academic and community-based oncologists and researchers and a member of the Georgia CORE Gynecologic Oncology Group Consortium. The center consists of eleven physicians with three clinics: medical oncology, gynecologic oncology and radiation oncology. The John B. Amos Cancer Center offers a medical team of experienced board-certified oncologists (MDs), advanced registered nurse practitioners, clinical researchers, case manager associates, clinical counselors, pharmacists, radiation physicists and therapists, oncology- and chemotherapy-certified nurses and registered dietitians.

Treatment Sites in Georgia

Clinical Trials in Georgia

A Double Blind Placebo-Controlled Trial of Eflornithine and Sulindac to Prevent Recurrence of High Risk Adenomas and Second Primary Colorectal Cancers in Patients With Stage 0-III Colon Cancer, Phase III - Preventing Adenomas of the Colon With Eflornithine and Sulindac (PACES)
Cancer Type: Unknown Primary
Study Coordinator: Jay Pitts, BS, CPhT - 706-596-5426


A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-small Cell Lung Cancer: Crizotinib Versus Placebo for Patients With Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Cancer Type: Lung Cancer
Study Coordinator: Jay Pitts, BS, CPhT - 706-596-5426


A Phase III Randomized Trial Comparing Androgen Deprivation Therapy + TAK-700 With Androgen Deprivation Therapy + Bicalutamide in Patients With Newly Diagnosed Metastatic Sensitive Prostate Cancer
Cancer Type: Prostate Cancer
Study Coordinator: Jay Pitts, BS, CPhT - 706-596-5426


Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Cancer Type: Lung Cancer

Adjuvant Nivolumab in Resected Lung Cancers (ANVIL) – A Randomized Phase III Study of Nivolumab after Surgical Resection and Adjuvant Chemotherapy in Non-small Cell Lung Cancers
Cancer Type: Lung Cancer
Study Coordinator: Jay Pitts, BS, CPhT - 706-596-5426


Connect® MDS/AML: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry
Cancer Type: Leukemia
Study Coordinator: Jay Pitts, BS, CPhT - 706-596-5426


EAY131: Molecular Analysis for Therapy Choice (NCI-MATCH)
Cancer Type: Eye Cancer, Lymphoma, Multiple Primaries, Non-Hodgkin Lymphoma, Solid Tumor, Unknown Primary
Study Coordinator: Jay Pitts, BS, CPhT - 706-596-5426


EROS: Engendering Reproductive Health within Oncologic Survivorship
Cancer Type: Unknown Primary
Study Coordinator: Jay Pitts, BS, CPhT - 706-596-5426


PHASE 3 RANDOMIZED, DOUBLE-BLIND, PLACEBO CONTROLLED, MULTICENTER STUDY TO COMPARE THE EFFICACY AND SAFETY OF LENALIDOMIDE (CC-5013) PLUS R-CHOP CHEMOTHERAPY (R2-CHOP) VERSUS PLACEBO PLUS R-CHOP CHEMOTHERAPY IN SUBJECTS WITH PREVIOUSLY UNTREATED ACTIVATED B-CELL TYPE DIFFUSE LARGE B-CELL LYMPHOMA
Cancer Type: Non-Hodgkin Lymphoma
Study Coordinator: Jay Pitts, BS, CPhT - 706-596-5426


Phase III Randomized Study of Androgen-Deprivation Therapy and High-Dose Radiotherapy With or Without Whole-Pelvic Radiotherapy in Patients With Unfavorable Intermediate- or Favorable High-Risk Prostate Cancer
Cancer Type: Prostate Cancer
Study Coordinator: Jay Pitts, BS, CPhT - 706-596-5426


Phase III Randomized Study of Pazopanib Hydrochloride in Patients With Metastatic Renal Cell Carcinoma Who Have No Evidence of Disease After Metastasectomy
Cancer Type: Kidney Cancer
Study Coordinator: Jay Pitts, BS, CPhT - 706-596-5426


Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Cancer Type: Breast Cancer
Study Coordinator: Jay Pitts, BS, CPhT - 706-596-5426


Randomized Double-Blind Placebo Controlled Study of Subcutaneous Testosterone in the Adjuvant Treatment of Postmenopausal Women With Aromatase Inhibitor Induced Arthralgias
Cancer Type: Breast Cancer
Study Coordinator: Jay Pitts, BS, CPhT - 706-596-5426


Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer
Cancer Type: Breast Cancer
Study Coordinator: Jay Pitts, BS, CPhT - 706-596-5426


RAnDomized Trial of SPI-2012 Versus Pegfilgrastim in the Management of Chemotherapy Induced Neutropenia in Breast CANCEr Patients Receiving Docetaxel and Cyclophosphamide (TC) (ADVANCE)
Cancer Type: Breast Cancer
Study Coordinator: Jay Pitts, BS, CPhT - 706-596-5426


S1400 Phase II/III Biomarker-Driven Master Protocol for Second Line Therapy of Squamous Cell Lung Cancer
Cancer Type: Lung Cancer
Study Coordinator: Jay Pitts, BS, CPhT - 706-596-5426